Compare Cenovus Energy Inc (CVE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Sana Biotechnology Inc — how do they compare? Cenovus Energy Inc trades at $31.36 (market cap $57.90B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Cenovus Energy Inc is far larger — about 69.2× Sana Biotechnology Inc's market cap, and Cenovus Energy Inc pays a 1.97% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Sana Biotechnology Inc for 23 Days on average.
| CVE | SANA | |
|---|---|---|
Market Cap | $57.90B | $836.71M |
Volume | 7,863,588 | 4,507,444 |
Sector | Energy | Health |
52-Week High | $33.92 | $5.92 |
52-Week Low | $15.85 | $2.68 |
Typical Hold Time | 46 Days | 23 Days |
Enterprise Value | $63.84B | $749.96M |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $31.39, up 2.48% with bullish technical signals and strong institutional support. The stock shows solid fundamentals with a P/E of 12.43, ROE of 20.96%, and consistent earnings beats in recent quarters. Recent analyst upgrades and positive media coverage highlight growing optimism around the company's growth prospects and attractive valuation metrics.
CVE presents a compelling investment case with strong profitability metrics and positive earnings momentum, though investors should monitor energy price volatility and execution risks. The company's improving cash flow outlook and shareholder returns through dividends provide additional support for long-term value creation.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
